Micafungin Salvage Mono-therapy in Invasive Aspergillosis

Status Terminated

Clinical Trial Summary

To evaluate the efficacy and safety of micafungin in patients with proven invasive aspergillosis and who are refractory or intolerant to previous systemic antifungal therapy. To compare the efficacy and safety of the micafungin therapy with the active control arm

Clinical Trial Description

This is a phase II, multicentre, prospective, active-controlled, open-label, 2:1 randomised and parallel group clinical study.

Patients will be stratified according to the baseline infection status and the baseline neutropenic status:

- Intolerant to previous antifungal therapy

- Refractory to previous antifungal therapy; progression of infection

- Refractory to previous antifungal therapy; failure to improve In case, criteria for both intolerant and refractory are fulfilled at the same time the patient will be considered as refractory.

- Neutropenic (absolute neutrophil count (ANC < 500 cells/mm3)

- Non neutropenic (ANC >= 500 cells/mm3) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00376337
Study type	Interventional
Source	Astellas Pharma Inc
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2006
Completion date	September 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06028451` - ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
Completed	`NCT00163722` - A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients	Phase 3
Completed	`NCT02394483` - Single Ascending Oral Dose Study of F901318	Phase 1
Completed	`NCT00404092` - Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis	Phase 2
Completed	`NCT01128907` - Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients	N/A
Recruiting	`NCT01386437` - Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Withdrawn	`NCT02912026` - Radiolabelled IV and Oral Metabolism Study of F901318	Phase 1
Withdrawn	`NCT03095547` - Drug/Drug Interactions With F901318	Phase 1
Withdrawn	`NCT03076905` - Pharmacokinetics of IV Formulation	Phase 1
Completed	`NCT02737371` - Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects	Phase 1
Terminated	`NCT00836875` - A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children	Phase 3
Active, not recruiting	`NCT00838643` - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	N/A
Terminated	`NCT04876716` - Azole-echinocandin Combination Therapy for Invasive Aspergillosis	Phase 3
Recruiting	`NCT05101187` - Olorofim Aspergillus Infection Study	Phase 3
Enrolling by invitation	`NCT02104479` - Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Not yet recruiting	`NCT05707832` - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus	Phase 3
Recruiting	`NCT06382922` - Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
Terminated	`NCT02396225` - Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration	N/A
Recruiting	`NCT00843804` - Surveillance for Nosocomial Infections in Pediatric Cancer Patients	N/A
Completed	`NCT00334412` - COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis	Phase 4